{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:08:17Z","timestamp":1775488097799,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Republic of Serbia Ministry of Education Science and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jpba.2025.116742","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T11:19:11Z","timestamp":1739186351000},"page":"116742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Development and robust optimization of the RP-HPLC method for the determination of riociguat and its four impurities in tablets using the AQbD approach"],"prefix":"10.1016","volume":"258","author":[{"given":"Milena","family":"Rmandi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-6832","authenticated-orcid":false,"given":"Marija","family":"Ra\u0161evi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Stankovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"Ze\u010devi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4747-927X","authenticated-orcid":false,"given":"Biljana","family":"Ota\u0161evi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Proti\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4102-3933","authenticated-orcid":false,"given":"An\u0111elija","family":"Malenovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2025.116742_bib1","unstructured":"ICH Harmonise Triparite Guideline Q8 (R2): Pharmaceutical Development, Avgust 2009. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-considerations-ich-guideline-q8-r2-pharmaceutical-development-step-5_en.pdf\u3009 (accessed 15 July 2024)."},{"key":"10.1016\/j.jpba.2025.116742_bib2","unstructured":"ICH International Conference on Harmonisation, Q14 Analytical Procedure Development, The European Agency for the Evaluation of Medicinal Products, 2022. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-q14-analytical-procedure-development-step-2b_en.pdf\u3009 (accessed 15 July 2024)."},{"key":"10.1016\/j.jpba.2025.116742_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.trac.2012.09.007","article-title":"Design spaces for analytical methods","volume":"42","author":"Rozet","year":"2013","journal-title":"Trends Anal. Chem."},{"key":"10.1016\/j.jpba.2025.116742_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.trac.2017.10.028","article-title":"\u2018Quality by design\u2019 approach for the analysis of impurities in pharmaceutical drug products and drug substances","volume":"101","author":"Dispas","year":"2018","journal-title":"Trends Anal. Chem."},{"key":"10.1016\/j.jpba.2025.116742_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jpba.2018.07.050","article-title":"Risk-based approach for method development in pharmaceutical quality control context: a critical review","volume":"161","author":"Deidda","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116742_bib6","unstructured":"European Pharmacopeia 11th Ed, Council of Europe, Strasbourg, Cedex, 2023."},{"key":"10.1016\/j.jpba.2025.116742_bib7","unstructured":"The United States Pharmacopoeia 48, United States Pharmacopoeial Convention, Rockville, USA, 2023."},{"key":"10.1016\/j.jpba.2025.116742_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcoa.2022.100058","article-title":"Identification and toxicity profiling of degradation impurities of riociguat using tandem mass spectrometry and in-silico studies","volume":"2","author":"Chodankar","year":"2022","journal-title":"J. Chromatogr. Open"},{"issue":"2","key":"10.1016\/j.jpba.2025.116742_bib9","first-page":"3060","article-title":"Method development and validation of riociguat by RP-HPLC","volume":"7","author":"Sirisha","year":"2016","journal-title":"Pharmanest - Int. J. Adv. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.jpba.2025.116742_bib10","first-page":"461","article-title":"Development and validation of reverse-phase high-performance liquid chromatography method for quantitative estimation of riociguat in tablet dosage form","volume":"12","author":"Temgire","year":"2018","journal-title":"J. Pharm. Res."},{"issue":"12","key":"10.1016\/j.jpba.2025.116742_bib11","first-page":"100","article-title":"Analytical quality by design-based LC-MS\/MS method for the determination of Riociguat in its formulations","volume":"11","author":"Nayak","year":"2021","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.jpba.2025.116742_bib12","series-title":"ICH Harmonized Guideline Q2 (R2): Validation of Analytical Procedures: Text and Methodology","year":"2024"},{"key":"10.1016\/j.jpba.2025.116742_bib13","series-title":"ICH Harmonized Guideline Q9 (R1): Quality Risk Management","year":"2023"},{"issue":"5","key":"10.1016\/j.jpba.2025.116742_bib14","article-title":"Lifecycle management of analytical procedures: method development, procedure performance qualification, and procedure performance verification","volume":"39","author":"Martin","year":"2013","journal-title":"Pharmacop. Forum"},{"key":"10.1016\/j.jpba.2025.116742_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115645","article-title":"Analytical method development supported by DoE-DS approach for enantioseparation of (S,S)- and (R,R)-moxifloxacin","volume":"235","author":"Ra\u0161evi\u0107","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116742_bib16","series-title":"Advances in Chromatography","first-page":"1","article-title":"Recent Progress in Fundamental Understanding and Practice of Chaotropic Chromatography: Rationalizing the Effects of Analytes\u2019 Structure with Pharmaceutical Applications","author":"Vemi\u0107","year":"2018"},{"issue":"7","key":"10.1016\/j.jpba.2025.116742_bib17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/chemosensors9070172","article-title":"Expediting disulfiram assays through a systematic analytical quality by design approach","volume":"9","author":"Basso","year":"2021","journal-title":"Chemosensors"},{"key":"10.1016\/j.jpba.2025.116742_bib18","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s42452-020-2890-1","article-title":"DoE based failure mode effect analysis (FMEA) to development of stability indicating HPTLC method for estimation of apremilast","volume":"2","author":"Prajapati","year":"2020","journal-title":"SN Appl. Sci."},{"key":"10.1016\/j.jpba.2025.116742_bib19","unstructured":"Chemicalize \u3008https:\/\/chemicalize.com\/welcome\u3009 (accessed 20 october 2023)."},{"key":"10.1016\/j.jpba.2025.116742_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.chroma.2004.11.104","article-title":"Reversed-phase high-performance liquid chromatography behavior of chaotropic counteranions","volume":"1064","author":"Kazakevich","year":"2005","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2025.116742_bib21","series-title":"Ion-Pair Chromatography and Related Techniques","author":"Cecchi","year":"2009"},{"issue":"5\u20136","key":"10.1016\/j.jpba.2025.116742_bib22","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0731-7085(00)00529-X","article-title":"Guidance for robustness\/ruggedness tests in method validation","volume":"24","author":"Vander Heyden","year":"2001","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116742_bib23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10337-018-3661-7","article-title":"Robust optimization of chaotropic chromatography assay for lamotrigine and its two impurities in tablets","volume":"82","author":"\u010colovi\u0107","year":"2019","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2025.116742_bib24","series-title":"Handbook of Modern Pharmaceutical Analysis","first-page":"415","article-title":"Validation of Pharmaceutical Test Methods","author":"Crowther","year":"2001"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525000834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525000834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T15:46:55Z","timestamp":1763999215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708525000834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":24,"alternative-id":["S0731708525000834"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116742","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1007\/s44371-025-00319-4","asserted-by":"object"}]},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and robust optimization of the RP-HPLC method for the determination of riociguat and its four impurities in tablets using the AQbD approach","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116742","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116742"}}